 Connection
Michael Bristow to Chronic Disease
This is a "connection" page, showing publications Michael Bristow has written about Chronic Disease.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.639 |
|
|
|
-
Bristow MR, Saxon LA, Feldman AM, Mei C, Anderson SA, DeMets DL. Lessons Learned and Insights Gained in?the?Design, Analysis, and Outcomes of?the COMPANION Trial. JACC Heart Fail. 2016 07; 4(7):521-535.
Score: 0.084
-
Bristow MR. Treatment of chronic heart failure with ?-adrenergic receptor antagonists: a convergence of receptor pharmacology and clinical cardiology. Circ Res. 2011 Oct 28; 109(10):1176-94.
Score: 0.061
-
Bader FM, Gilbert EM, Mehta NA, Bristow MR. Double-blind placebo-controlled comparison of enoximone and dobutamine infusions in patients with moderate to severe chronic heart failure. Congest Heart Fail. 2010 Nov-Dec; 16(6):265-70.
Score: 0.057
-
Sumner AD, Boehmer JP, Saxon LA, Carson P, Feldman AM, Galle E, Bristow MR. Statin use is associated with improved survival in patients with advanced heart failure receiving resynchronization therapy. Congest Heart Fail. 2009 Jul-Aug; 15(4):159-64.
Score: 0.052
-
Bristow MR, Saxon LA, Boehmer J, Krueger S, Kass DA, De Marco T, Carson P, DiCarlo L, DeMets D, White BG, DeVries DW, Feldman AM. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med. 2004 May 20; 350(21):2140-50.
Score: 0.037
-
Bristow M. Antiadrenergic therapy of chronic heart failure: surprises and new opportunities. Circulation. 2003 Mar 04; 107(8):1100-2.
Score: 0.034
-
Shakar SF, Bristow MR. Low-level inotropic stimulation with type III phosphodiesterase inhibitors in patients with advanced symptomatic chronic heart failure receiving beta-blocking agents. Curr Cardiol Rep. 2001 May; 3(3):224-31.
Score: 0.030
-
Bristow MR, Feldman AM, Saxon LA. Heart failure management using implantable devices for ventricular resynchronization: Comparison of Medical Therapy, Pacing, and Defibrillation in Chronic Heart Failure (COMPANION) trial. COMPANION Steering Committee and COMPANION Clinical Investigators. J Card Fail. 2000 Sep; 6(3):276-85.
Score: 0.028
-
Bristow MR. Mechanistic and clinical rationales for using beta-blockers in heart failure. J Card Fail. 2000 Jun; 6(2 Suppl 1):8-14.
Score: 0.028
-
Bristow MR. beta-adrenergic receptor blockade in chronic heart failure. Circulation. 2000 Feb 08; 101(5):558-69.
Score: 0.027
-
Bristow M, Port JD. Beta-adrenergic blockade in chronic heart failure. Scand Cardiovasc J Suppl. 1998; 47:45-55.
Score: 0.024
-
Bristow MR. Mechanism of action of beta-blocking agents in heart failure. Am J Cardiol. 1997 Dec 04; 80(11A):26L-40L.
Score: 0.023
-
Bristow MR, Abraham WT, Yoshikawa T, White M, Hattler BG, Crisman TS, Lowes BD, Robertson AD, Larrabee P, Gilbert EM. Second- and third-generation beta-blocking drugs in chronic heart failure. Cardiovasc Drugs Ther. 1997 May; 11 Suppl 1:291-6.
Score: 0.022
-
Eichhorn EJ, Bristow MR. Practical guidelines for initiation of beta-adrenergic blockade in patients with chronic heart failure. Am J Cardiol. 1997 Mar 15; 79(6):794-8.
Score: 0.022
-
Bristow MR, Gilbert EM, Abraham WT, Adams KF, Fowler MB, Hershberger RE, Kubo SH, Narahara KA, Ingersoll H, Krueger S, Young S, Shusterman N. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. MOCHA Investigators. Circulation. 1996 Dec 01; 94(11):2807-16.
Score: 0.022
-
Eichhorn EJ, Bristow MR. Medical therapy can improve the biological properties of the chronically failing heart. A new era in the treatment of heart failure. Circulation. 1996 Nov 01; 94(9):2285-96.
Score: 0.022
-
Bristow MR. Pathophysiologic and pharmacologic rationales for clinical management of chronic heart failure with beta-blocking agents. Am J Cardiol. 1993 Mar 25; 71(9):12C-22C.
Score: 0.017
-
Metra M, Eichhorn E, Abraham WT, Linseman J, B?hm M, Corbalan R, DeMets D, De Marco T, Elkayam U, Gerber M, Komajda M, Liu P, Mareev V, Perrone SV, Poole-Wilson P, Roecker E, Stewart J, Swedberg K, Tendera M, Wiens B, Bristow MR. Effects of low-dose oral enoximone administration on mortality, morbidity, and exercise capacity in patients with advanced heart failure: the randomized, double-blind, placebo-controlled, parallel group ESSENTIAL trials. Eur Heart J. 2009 Dec; 30(24):3015-26.
Score: 0.013
-
Metra M, Nodari S, D'Aloia A, Muneretto C, Robertson AD, Bristow MR, Dei Cas L. Beta-blocker therapy influences the hemodynamic response to inotropic agents in patients with heart failure: a randomized comparison of dobutamine and enoximone before and after chronic treatment with metoprolol or carvedilol. J Am Coll Cardiol. 2002 Oct 02; 40(7):1248-58.
Score: 0.008
-
Swedberg K, Bristow MR, Cohn JN, Dargie H, Straub M, Wiltse C, Wright TJ. Effects of sustained-release moxonidine, an imidazoline agonist, on plasma norepinephrine in patients with chronic heart failure. Circulation. 2002 Apr 16; 105(15):1797-803.
Score: 0.008
-
Eichhorn EJ, Domanski MJ, Krause-Steinrauf H, Bristow MR, Lavori PW. A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. N Engl J Med. 2001 05 31; 344(22):1659-67.
Score: 0.007
-
Fowler MB, Vera-Llonch M, Oster G, Bristow MR, Cohn JN, Colucci WS, Gilbert EM, Lukas MA, Lacey MJ, Richner R, Young ST, Packer M. Influence of carvedilol on hospitalizations in heart failure: incidence, resource utilization and costs. U.S. Carvedilol Heart Failure Study Group. J Am Coll Cardiol. 2001 May; 37(6):1692-9.
Score: 0.007
-
Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, Shusterman NH. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med. 1996 May 23; 334(21):1349-55.
Score: 0.005
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|